Tetraphase Pharmaceuticals
TTPH
TTPH was delisted on the 28th of July, 2020.
73 hedge funds and large institutions have $286M invested in Tetraphase Pharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 22 increasing their positions, 17 reducing their positions, and 9 closing their positions.
89% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 9
29% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 17
14% more funds holding
Funds holding: 64 → 73 (+9)
2% less capital inflows, than outflows
Capital inflows: $43.1M | Capital outflows: $44M
6% less call options, than puts
Call options by funds: $2.16M | Put options by funds: $2.29M
8.3% less ownership
Funds ownership: 55.03% → 46.73% (-8.3%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$6.76M |
| 2 |
Fidelity International
Hamilton,
Bermuda
|
+$5.96M |
| 3 |
Columbia Partners Investment Management
Alexandria,
Virginia
|
+$5.11M |
| 4 |
Granahan Investment Management
Waltham,
Massachusetts
|
+$4.13M |
| 5 |
Nomura Holdings
Tokyo,
Japan
|
+$3.39M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Broadfin Capital
New York
|
-$15.5M |
| 2 |
AIC
AWM Investment Company
New York
|
-$10.9M |
| 3 |
PointState Capital
New York
|
-$5.36M |
| 4 |
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.62M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.84M |
TTPH Hedge Fund Activity: Q3 2014 in Review
73 of the 3,454 institutional investors tracked by Wall St. Rank reported a position in Tetraphase Pharmaceuticals (TTPH) for Q3 2014, worth a combined $286M — up 54% from $185M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new TTPH positions and 9 closed out — a net gain of 8 holders — while 22 added to existing stakes and 17 trimmed.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $6.76M. The largest seller was Broadfin Capital, cutting an estimated $15.5M.
- 73 institutional investors held Tetraphase Pharmaceuticals (TTPH) as of Q3 2014, up from 64 in Q2 2014.
- Funds reported $286M of Tetraphase Pharmaceuticals stock for Q3 2014, up 54% quarter-over-quarter.
- 17 funds opened new Tetraphase Pharmaceuticals positions in Q3 2014 and 9 closed out, a net change of +8 holders.
- The largest Tetraphase Pharmaceuticals buyer in Q3 2014 was Adage Capital Partners, an estimated $6.76M added.
- The largest Tetraphase Pharmaceuticals seller in Q3 2014 was Broadfin Capital, an estimated $15.5M sold.
Based on aggregated 13F filings for Q3 2014.